Rion is focused on developing clinically impactful, accessible, and practical therapies using innovative regenerative medicine technologies based on extracellular vesicle science. Founded from breakthrough research at Mayo Clinic, Rion has developed Purified Exosome Product (PEP), an innovative biologic platform that harnesses the therapeutic power of exosomes as a truly shelf-stable regenerative medicine. PEP can be customized to different routes of administration to target specific tissues and diseases, and has the potential to address significant unmet patient needs in many fields of medicine. The company is currently evaluating PEP in clinical and preclinical studies for several soft tissue diseases, including wound healing, cardiovascular disease, and womens’ health.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):